Benchmark restated their buy rating on shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $95.00 price target on the biotechnology company’s stock. A number of other brokerages also recently weighed in on LGND. TheStreet downgraded shares of Ligand Pharmaceuticals from […]
StockNews.com lowered shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a buy rating to a hold rating in a research note released on Wednesday morning. Several other brokerages also recently weighed in on LGND. HC Wainwright reaffirmed a buy rating and set a $144.00 target price on shares of Ligand Pharmaceuticals in a research […]
Ligand Pharmaceuticals (NASDAQ:LGND) Lowered to Hold at StockNews.com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned an average recommendation of “Buy” from the four brokerages that are currently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have covered the stock in […]
HC Wainwright restated their buy rating on shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) in a research report released on Wednesday morning, Benzinga reports. The firm currently has a $144.00 price objective on the biotechnology company’s stock. LGND has been the topic of a number of other research reports. Barclays cut their price target […]